133 related articles for article (PubMed ID: 8647143)
21. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
Aus G
Scand J Urol Nephrol Suppl; 1994; 167():1-41. PubMed ID: 7542397
[TBL] [Abstract][Full Text] [Related]
22. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.
Blana A; Brown SC; Chaussy C; Conti GN; Eastham JA; Ganzer R; Murat FJ; Pasticier G; Rebillard X; Rewcastle JC; Robertson CN; Thuroff S; Ward JF
BJU Int; 2009 Oct; 104(8):1058-62. PubMed ID: 19388986
[TBL] [Abstract][Full Text] [Related]
23. Transrectal high-intensity focused ultrasound for treatment of localized prostate cancer.
Inoue Y; Goto K; Hayashi T; Hayashi M
Int J Urol; 2011 May; 18(5):358-62. PubMed ID: 21449970
[TBL] [Abstract][Full Text] [Related]
24. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients.
Crouzet S; Chapelon JY; Rouvière O; Mege-Lechevallier F; Colombel M; Tonoli-Catez H; Martin X; Gelet A
Eur Urol; 2014 May; 65(5):907-14. PubMed ID: 23669165
[TBL] [Abstract][Full Text] [Related]
25. Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer.
Ficarra V; Antoniolli SZ; Novara G; Parisi A; Fracalanza S; Martignoni G; Artibani W
BJU Int; 2006 Dec; 98(6):1193-8. PubMed ID: 17125477
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of prostatic cancer with high intensity focused ultrasound (HIFU) using Ablatherm device].
Aliaev IuG; Krupinov GE; Bezrukov EA; Grigorian VA; Amosov AV; Chalyĭ ME; Kobzev DN; Bruk IuF; Shestiperov PA
Urologiia; 2007; (6):39-44. PubMed ID: 18649659
[TBL] [Abstract][Full Text] [Related]
27. Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer.
Rebillard X; Gelet A; Davin JL; Soulie M; Prapotnich D; Cathelineau X; Rozet F; Vallancien G
J Endourol; 2005; 19(6):693-701. PubMed ID: 16053358
[TBL] [Abstract][Full Text] [Related]
28. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
29. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer.
Murat FJ; Poissonnier L; Rabilloud M; Belot A; Bouvier R; Rouviere O; Chapelon JY; Gelet A
Eur Urol; 2009 Mar; 55(3):640-7. PubMed ID: 18508188
[TBL] [Abstract][Full Text] [Related]
30. Hemi salvage high-intensity focused ultrasound (HIFU) in unilateral radiorecurrent prostate cancer: a prospective two-centre study.
Baco E; Gelet A; Crouzet S; Rud E; Rouvière O; Tonoli-Catez H; Berge V; Chapelon JY; Eggesbø HB
BJU Int; 2014 Oct; 114(4):532-40. PubMed ID: 24930692
[TBL] [Abstract][Full Text] [Related]
31. High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology.
Rebillard X; Soulié M; Chartier-Kastler E; Davin JL; Mignard JP; Moreau JL; Coulange C;
BJU Int; 2008 May; 101(10):1205-13. PubMed ID: 18325057
[TBL] [Abstract][Full Text] [Related]
32. High-intensive focused ultrasound in localized prostate cancer.
Chaussy CG; Thüroff S
J Endourol; 2000 Apr; 14(3):293-9. PubMed ID: 10795622
[TBL] [Abstract][Full Text] [Related]
33. Transrectal high-intensity focused ultrasound using the Ablatherm device in the treatment of localized prostate carcinoma.
Beerlage HP; Thüroff S; Debruyne FM; Chaussy C; de la Rosette JJ
Urology; 1999 Aug; 54(2):273-7. PubMed ID: 10443724
[TBL] [Abstract][Full Text] [Related]
34. [The role of the absolute value and "density" of the prostate-specific antigen estimated echographically in the selection of patients to undergo a biopsy in suspected prostatic carcinoma. A comparison between PSA, palpation and echography in 95 patients undergoing echo-guided endorectal prostatic biopsy].
Di Donna A; Bazzocchi M; Guerra UP; Bendini M; De Biasi F; Caminiti F; Delendi M
Radiol Med; 1993; 85(1-2):84-9. PubMed ID: 7683136
[TBL] [Abstract][Full Text] [Related]
35. Treatment of localized prostate cancer using high-intensity focused ultrasound.
Uchida T; Ohkusa H; Nagata Y; Hyodo T; Satoh T; Irie A
BJU Int; 2006 Jan; 97(1):56-61. PubMed ID: 16336329
[TBL] [Abstract][Full Text] [Related]
36. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
37. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
38. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer.
Ganzer R; Rogenhofer S; Walter B; Lunz JC; Schostak M; Wieland WF; Blana A
Eur Urol; 2008 Mar; 53(3):547-53. PubMed ID: 17662520
[TBL] [Abstract][Full Text] [Related]
39. Location of residual cancer after transrectal high-intensity focused ultrasound ablation for clinically localized prostate cancer.
Boutier R; Girouin N; Cheikh AB; Belot A; Rabilloud M; Gelet A; Chapelon JY; Rouvière O
BJU Int; 2011 Dec; 108(11):1776-81. PubMed ID: 21711432
[TBL] [Abstract][Full Text] [Related]
40. Ferromagnetic thermal ablation of locally recurrent prostate cancer: prostate specific antigen results and immediate/intermediate morbidities.
Master VA; Shinohara K; Carroll PR
J Urol; 2004 Dec; 172(6 Pt 1):2197-202. PubMed ID: 15538231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
